Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation.

Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) usually confers poor prognosis and high mortality. Currently, therapeutic options are limited. Here we report an 18-year-old man with acute myeloid leukemia developed BOS after allo-HCT and responded poorly to inhaled corticosteroids and short-acting beta-agonist, azithromycin, montelukast, and immunosuppressants. Then he started nintedanib treatment, and the symptoms of nonproductive cough and dyspnea were alleviated gradually. His pulmonary function test revealed increased FEV1 compared to baseline.